The biologic effects of retinoids such as all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid on proliferation and differentiation of hematopoietic cells are mediated by binding and activating two distinct families of transcription factors: the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). The RARs require heterodimerization with RXRs; in addition, RXRs can form homodimers, which can bind t o DNA response elements that are either distinct or the same as those bound by the RAR/RXR heterodimers. Therefore, the two retinoid pathways provide sequences that are specificfor effective DNA binding and activation of target genes. We have developed several series of novel synthetic retinoids that selectively interact with RXR/RXR homodimers and RAR/RXR heterodimers. We show here that SR11236 and SR11246, which are RXR-selective analogs, had little ability t o inhibit clonal growth and induce differentiation of leukemic cells (HL-60 cells and fresh acute myeloid leukemia cells). However, SR11249, SR11256, and LGD1069, which activated both RXR/RXR homodimers and RAR/RXR heterodimers, could inhibit clonal growth and induce differentia-HE RETINOID all-trans-retinoic acid (ATRA) has a T critical role in many aspects of proliferation and differentiation of a wide variety of cell types and is a clinically useful anticancer agent, having profound effects on hematopoietic cells.',2 ATRA stimulates clonal growth of normal human myeloid and erythroid precursors in vitro and inhibits proliferation and induces differentiation of blast cells from some patients with acute myelogenous leukemia (AML).3 Investigations in vitro have shown that ATRA induces differentiation of the human myeloid leukemia cell line known as HL-60 and acute promyelocytic leukemia (APL) cells from patient^.^^^ Also, a study has revealed that ATRA inhibited the proliferation of clonogenic acute myelogeneous leukemic cells, even though these cells could not be induced to differentiate.' Recent studies have shown that a high proportion of patients with APL achieve complete remission after treatment with ATRA.6-9
The biologic effects of retinoids such as all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid on proliferation and differentiation of hematopoietic cells are mediated by binding and activating two distinct families of transcription factors: the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). The RARs require heterodimerization with RXRs; in addition, RXRs can form homodimers, which can bind t o DNA response elements that are either distinct or the same as those bound by the RAR/RXR heterodimers. Therefore, the two retinoid pathways provide sequences that are specificfor effective DNA binding and activation of target genes. We have developed several series of novel synthetic retinoids that selectively interact with RXR/RXR homodimers and RAR/RXR heterodimers. We show here that SR11236 and SR11246, which are RXR-selective analogs, had little ability t o inhibit clonal growth and induce differentiation of leukemic cells (HL-60 cells and fresh acute myeloid leukemia cells). However, SR11249, SR11256, and LGD1069, which activated both RXR/RXR homodimers and RAR/RXR heterodimers, could inhibit clonal growth and induce differentia-HE RETINOID all-trans-retinoic acid (ATRA) has a T critical role in many aspects of proliferation and differentiation of a wide variety of cell types and is a clinically useful anticancer agent, having profound effects on hematopoietic cells.',2 ATRA stimulates clonal growth of normal human myeloid and erythroid precursors in vitro and inhibits proliferation and induces differentiation of blast cells from some patients with acute myelogenous leukemia (AML). 3 Investigations in vitro have shown that ATRA induces differentiation of the human myeloid leukemia cell line known as HL-60 and acute promyelocytic leukemia (APL) cells from patient^.^^^ Also, a study has revealed that ATRA inhibited the proliferation of clonogenic acute myelogeneous leukemic cells, even though these cells could not be induced to differentiate.' Recent studies have shown that a high proportion of patients with APL achieve complete remission after treatment with ATRA. [6] [7] [8] [9] Studies of the molecular mechanisms of action of retinoids have revealed that they exert their effects by binding to retinoic acid receptors (RARs) and retinoid X receptors (RXRs)."-12 Both RARs (RARa, RARP, and RARy) and RXRs (RXRa, RXRP, and RXRy) are ligand-dependent transcription factors and belong to the steroidthyroid receptor ~uperfamily.'~.'~ Myeloid leukemia cells, including the HL-60 cell line, express RARa, RARP, and RXRa, although RARa levels are higher than RARfi. '5-20 The RARs bind ATRA as well as 9-cis-retinoic acid (9-&-RA); the latter, but not the former, is the ligand for the RXRS.~','' The RARs act effectively by heterodimerizing to form RAR/RXR comp l e~e s~~.~~; the RXRs act predominantly as coregulators enhancing the binding of the RAR and the vitamin D3, thyroid hormone, and peroxisome proliferator-activated receptors to their response elements via heterodimers." In the presence of 9-cis-RA, the RXR can also form homodimers, a finding that suggests that several different pathways exist for retition of HL-60 cells as well as leukemic cells from patients, including those with acute promyelocytic leukemia (APL). This is similar t o results observed with RAR/RXR-specific ligands. Interestingly, the combination of ATRA and either SR11249, SR11256, or LGD1069 showed synergistic effects in inducing differentiation of HL-60 cells. A retinoid (SRI12381 with strong anti-AP-1 activity that did not activate the RARs and RXRs for gene transcription from the response element TREpal was inactive in our assay systems, suggesting that the antiproliferative effects of retinoids on leukemic cells is not mediated by inhibiting the AP-1 pathway. We conclude that the RAR/RXR pathway is more important than RXR/RXR pathway for differentiation and proliferation of acute myeloid leukemic cells, and certain retinoids or combination of retinoids with both RAR and RXR specificities may synergistically enhance the differentiation activity of ATRA, which may be relevant in several clinical situations.
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noids to mediate their effects. Thus, 9-cis-RA may elicit a broad range of biologic reponses.
Studies showed that 9-cis-RA and ATRA induced differentiation and inhibited proliferation of AML cell lines and fresh leukemic cells from patients, and 9-cis-RA often showed a modest increase in potency as compared with ATRA.17.29 Moreover, we found that 9-cis-RA in combination with ATRA was an effective inducer of differentiation of an RA-resistant HL-60 variant cell line.30 However, the biologic role of RXR/RXR homodimers in hematopoiesis is still unclear. Recently, a novel class of synthetic retinoids was demonstrated to have greater selectivity for activation of RXR/RXR homodimers rather than RAR/RXR heterodi- Relative response compared with mol/L ATRA (100%) for RARs and mol/L 9-cis-RA (100%) for RXRa.
In this study, we performed structure-function analysis to identify the characteristics of retinoids that allow them to induce differentiation and inhibit proliferation of acute myeloid leukemic cells.
MATERIALS AND METHODS

Cells.
Myeloid leukemia lines used in this study were KG-1 and HL-60 cells. Leukemic samples from bone marrow or peripheral blood from eight consenting AML patients were collected in heparinized tubes before any therapy. Three patients had APL M3, three patients had MI, and two had M2. The percentage of circulating blast cells was more than 80% of the mononuclear population at the time of harvesting the cells. The diagnosis was established according to French-American-British (FAB) e rite ria.^' The leukemic cells were isolated by Ficoll-Hypaque (Lymphoprep; Nycomed Pharma AS, Oslo, Norway; density, 1.077 g/mL) gradient centrifugation, washed twice in phosphate-buffered saline (PBS), and enriched after monocyte adherence to plastic for 1 hour at 37°C. The blast cells were immediately placed into suspension culture containing RPMI 1640 medium with 10% fetal bovine serum (FBS; GIBCO BRL, Grand Island, NY), 100 U/mL penicillin, and 100 j&mL streptomycin in humidified air/5% CO2.
ATRA was purchased from Sigma Chemical CO (St. Louis, MO), and 9-cis-RA was a gift from Dr M. Klaus (F. Hoffmann-La Roche, Basel, Switzerland). Synthetic ligands used in this study included 2-(4-~arboxyphenyl)- (Fig 1) . Retinoids were dissolved in 100% ethanol to a stock concentration of lo-' mol& stored at -20"C, and protected from light. In each experiment, controls were run using the same concentration of ethanol as was present in the experimental plates. This concentration of diluant had no effect on proliferation of cells.
Transient transfections of CV-1 cells were performed using the calcium phosphate precipitation procedure, as described prev i~u s l y .~~ Approximately 5 X IO5 cells were transfected with 50 ng of expression vector for either human RARa, RARP, RARy, or
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RXRu,14 100 ng of reporter gene, and 150 ng of the P-galactosidase expression plasmid pCHl IO. After transfection, cells were grown in the presence or absence of retinoids for 20 hours3' before determination of the levels of the reporter chloramphenicol acetyl transferase. Results were corrected for control P-galactosidase expression.
HL-60 cells were plated at 2 X lo3 cells per plate in six-well culture dishes in a two-layer, soft-agar system according to previously described methods." For analysis of myeloid cell leukemic clonal growth, I X 10' blast cells were plated and retinoids were added as indicated. After incubation for 10 days, colonies ( 2 4 0 cells) were counted using an inverted microscope. All experiments were performed using triplicate plates per experimental point; each experiment was performed three times. The results were expressed as the mean percentage of clonal growth in plates containing retinoids as compared with the number of colonies in control dishes without retinoids. For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From cell suspension (2 x IO5 cells per milliliter) was mixed with an equal volume of solution containing 1.25 mg/mL NBT (Sigma), 17 mg/mL bovine serum albumin (fraction V; Sigma), and 1 m g l d 12-0-tetradecanoy1phorbol-13-acetate (TPA; Sigma) for 30 minutes at 37°C. After incubation, the medium was discarded, and the formazan deposits were dissolved by adding 0.1 mL of dimethyl sulfoxide (DMSO; Sigma) and measured at 580 nm. For analysis of cell-surface antigens, a two-color direct immunofluorescence staining technique was used. Cells were incubated for 60 minutes with human AB serum (Sigma) to block Fc receptors and were then exposed to phycoerythrin (PE)-conjugated mouse antihuman CD11 b and fluorescein isothiocyanate (FITC)-conjugated mouse antihuman CD14 (Beckton Dickinson, Mountain View, CA). Control studies were performed with a nonbinding control mouse IgGl isotype antibody (Beckton Dickinson). Analysis of fluorescence was performed on a FACScan flow cytometer (Beckton Dickinson).
RESULTS
Effect of retinoids on transactivation of a reporter gene having RAR and RXR response sequences. In Table 1 are presented the retinoid receptor transcriptional activities on the TREpal of nine retinoids in the presence of RARa, RARP, RARy, and RXRa. The TREpal response element, which was used in the transfection assay, is responsive to both RAR and RXR dimer complexes that have been activated by retinoids. The retinoids, the structures of which are shown in Fig 1, show a range of activities for these retinoid receptors, particularly RXRa.
For example, retinoid SRI 1236 selectively activates RXRa (59%) at lo-' m o m . It does not activate either RARa or RARD at IO-' m o m , but does activate RARa (34%) at lo-, m o m . SRI1236 also lacks anti-AP-1 activity, as it does not inhibit the activation of the collagenase promoter in a reporter construct by the AP-I JunlFos complex in the presence of any of the retinoid receptors (Table 2 ). In contrast, its analog, SR11238, does not activate any of these receptors to induce gene transcription but is capable of inhibiting AP-1 activity. SR11246 is the most RXR-selective of the seven retinoids because it does not activate any of the RARs at m o m . SR11249 demonstrates selective activity for RARP and RXRa at concentrations as low as m o m (34% and 49%, respectively), whereas its analog SRI 1269 activates RARP (45%) and RXRa (104%) at IO-' mol/L but only activates RARa at m o m (45%).
LG1069 also demonstrates panagonist activity by activating both retinoid receptor subclasses: RARa (38%), RARP (52%), and RXRa (72%) at lo-' m o m . SR11256 also demonstrates some panagonist activity by activating RXRa (70%) at m o m , but not (15%) at lo-' m o m , and by activating the RARs, on which it is far more potent, giving activations greater than 60% for RXRa and RARP at lo-' mol/L.
Effects of retinoids on proliferation of leukemic cells in soji gel culture. The retinoids were examined for their effect on clonogenic proliferation of HL-60 cells (Fig 2, Table  2 ). Retinoids SRI 1236, SRI 1238, SRI 1246, and SRI 1269 were poor inhibitors (less than 20%) of leukemic colony formation, and LGD1069 m o m ) inhibited colony formation by 37%. These compounds showed greater selectivity for RXR than RAR. Analogs SR11249 and SR11256 had effective doses that inhibited 50% colony formation (ED,,) of approximately lo-* m o m . Both 9-cis-RA and ATRA had an ED50 of about 5 X m o m for inhibition of clonal growth of HL-60 cells.
The effects of ATRA and retinoids SRI 1236, SRI 1238, and SR11249 on proliferation of fresh leukemic cells from patients paralleled those observed with HL-60 cells (Fig 3) . (Fig 4, upper left panel) . In combination with either ATRA mom) or 9-cis-RA mom), SR11249 showed a slightly additive effect (Fig 4, upper right panel) . The induction of NBT activity in leukemic cells from patients with APL by these same synthetic retinoids either alone or in combination with either ATRA or 9-cis-RA showed results comparable with those observed with the HL-60 cells (Fig 4, lower panels) .
&-RA
The expression of CD1 l b increases as myeloid cells differentiate towards granulocytes. Exposure of HL-60 cells to increasing concentrations of ATRA (lo-" to mom)
resulted in an increase in expression of CDllb in a doseresponse manner, with mom ATRA producing an approximately 10-fold greater expression of CD1 l b compared with that of untreated HL-60 cells (Fig 5) . The RXR-selective retinoids SRI 1236, SR11246, and SR11269 (lo-" to For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From 
DISCUSSION
Recent studies have shown that RARs require heterodimerization with RXRs for effective DNA binding and function23-28 and that RXRs bind several other ligand-regulated receptors, including thyroid hormone receptors (TR) and vitamin D3 re~eptors.'~-'~.~~ The RXRs can form either RXW RXR homodimers or RAFURXR heterodimers in the presence of 9-cis-RA." We have previously shown that 9-cis-RA was slightly more potent than ATRA in inhibiting proliferation and inducing differentiation of both myeloid leukemia cell lines and fresh APL How retinoids
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Retinoid (MJ regulate various aspects of differentiation and proliferation of leukemic cells still remains unclear. The role of RXW RXR homodimers and RXR/RAR heterodimers in hematopoiesis is unknown. To examine this issue, we investigated the effects of several new retinoids with defined RAR and RXR specificities, either alone or in combination with either ATRA or 9-cis-RA, on the in vitro growth and differentiation of the myeloid leukemic cell line, HL-60, as well as of fresh leukemic blasts from patients with AML, including those with APL. A summary of the salient data is shown in Table  2 .
Retinoids SR11236, SR11246, and SR11269 were extremely weak inhibitors of proliferation and inducers of differentiation of myeloid leukemic cells. SRI 1236, SR11246, and SR11269 predominantly activate RXR/RXR homodimers in the cotransfection assay, but do not activate RARa and RARP at concentrations up to lo-' m o m (SR11236 and SRI 1246) or weakly activate these receptors (SR11269), resulting in the modulation of RXR-selective response pathways. We conclude, therefore, that RXR/RXR-selective retinoids do not have a prominent effect on growth and differentiation of leukemic cells. SR11217, another ligand selective for RXR/RXR homodimers, also had little effect on either inducing differentiation or inhibiting clonal growth of myeloid leukemic cells. 37 The retinoids SR11249 and SR11256 in this series were nearly as active as ATRA in our leukemic models and had the ability to activate both RAR/RXR and RXR/RXR ( Table 2 ). The retinoid 4-(5,6,7$-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)benzoic acid (TTAB) is also a potent inducer of differentiation and inhibitor of clonal growth of leukemic cells, and it too is RAR/RXR-specific." These results suggest that RAR/RXR probably is the specific target that modulates proliferation and differentiation of hematopoietic cells.
The situation may be more complicated when the effects of two retinoids are examined simultaneously. When ATRA and the RXR/RXR-selective ligands SR11236, SR11238, SR11246, or SR11269 are combined, the expression of CDllb by HL-60 cells was no greater than when ATRA was added alone (Fig 5) . In contrast, when either SRI 1249, SR11256, or LGD1069 was added to ATRA, a marked synergy occurred in the expression of CDllb (Fig 5) . If these retinoids mediated their activities exactly like ATRA (eg, through the same RAR/RXR retinoic acid response elements), synergy should not have occurred. We do not know how to explain this phenomenon. Because the RXR/RXRselective analogs did not synergize with ATRA, perhaps the synergy requires the somewhat hybrid nature (RAWRXRand RXR/RXR-activating capacities) of retinoids SR11249 and SR11256. This may also explain why 9-cis-RA is slightly more active than ATRA and why it may act synergistically with ATRA.38 Another receptor or response element may also be involved. Perhaps these compounds bind to either RARP or RXRa to activate a heterodimer on this response element. Clarification of the mechanism of enhancement will require the identification and study of the genes critical for retinoid modulation of hematopoiesies.
Comparison of the clonal proliferation and differentiation results of HL-60 cells with the retinoid receptor transcriptional activation results for these retinoids is hampered because the retinoid response elements responsible for retinoid action in HL-60 cells have yet to be identified. Retinoid activation effects on particular receptors will depend on the response element involved (M.P. and M.I.D., unpublished data, August 1995). Therefore, the authentic HL-60 retinoid response elements may provide somewhat different results than those obtained using the synthetic TREpal. Nevertheless, several conclusions can be made on comparison of these data. Only three of the synthetic retinoids, SR11249, SR11256, and LG1069, were able to inhibit effectively the proliferation of HL-60 cells at mom and induce the expression of the differentiation marker CDl l b at lo-' mol/ L. The first two retinoids were the most potent and showed EDs0 values comparable with those of ATRA and 9-cis-RA. Only SR11256 was capable of activating RARa at mol/ L, but only activated RXRa by 15% at this concentration. SR11249 and LG1069 were potent activators of RXRa at m o m (57% and 95%, respectively), but their activation
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From of RARa was 510%. All three retinoids were able to activate RARP at mom. Therefore, activation of RARP may be involved in inhibition of proliferation and induction of differentiation mediated by retinoids. Of the other retinoids evaluated, only SR11269 showed a similar transcriptional activation profile on the TREpal; however, it was a far less potent activator of RARP. At mom, SR11269 did not activate RARa but did activate RXRa. Although its activation of RARP (46%) at m o m was comparable with that (52%) of LG1069, its activation of RARP at m o m dropped to 3% compared to 23% for LG1069.
Takahashi and Breitman39 have recently reported that the RARa-selective retinoid Am80 is able to induce the differentiation of HL-60 cells in medium containing serum, but is unable to do so in the absence of serum. Addition of ATRA to Am80 in the absence of serum fully induced HL-60 cell differentiation. These results indicate that activation of RARa alone is not sufficient to induce HL-60 cell differentiation and that another receptor(s) is involved. Our results using SR11249, SR11256, and LG1069 suggest that the other retinoid receptor involved in inhibition of proliferation and induction of differentiation by retinoids may be either RARP or an RXR. Because the RXR-selective retinoid SR11246, which efficiently activates the RXR homodimer, is inactive in the HL-60 cell assay and because SR11256, which is a potent activator of RARs but not RXRa, is active in this assay, it appears likely that RARP has an important role in proliferation inhibition and the induction of CD1 lb.
Our experiments, which are shown in Fig 4, demonstrate that the ability of the various analogs to induce differentiation of fresh APL cells from patients paralleled their abilities to induce differentiation of HL-60. These results suggest two points. First, HL-60 cells may be a good model for APL cells, even though they have different genetic changes. Second, perhaps the activity of retinoids on APL cells is independent of its genetic alterations. APL cells have a balanced translocation of part of the PML gene and the RARa gene and express PMLiRARa and RARaffML fusion proteins as well as a normal RARa and PML. We have found that NB4 cells (APL cell line; data not shown), APL cells, and HL-60 cells respond similarly to the various retinoids. Nevertheless, HL-60 cells do not express PMLRARa. Likewise, some AML samples at the late M-2 stage (FAB classification) of development, but not at an earlier stage of differentiation, are responsive to ATRA and 9-cis-RA." Perhaps the sensitivity of APL blast cells to induction of differentiation by retinoids is not related directly to their PML/RARa fusion gene product, but is more related to their relatively mature stage of differentiation. Both APL and HL-60 have this in common. Clearly, more studies are required to determine how retinoids induce differentiation of AML cells.
SR11238 is a member of a new class of retinoids that selectively inhibits AP-1 activity but does not activate tran~cription.'~ This retinoid did not induce the differentiation of F9 neuroblastoma cells but was able to inhibit the proliferation of the lung and breast cancer cell lines Calu-6 and T-47D, as well as HeLa cervical cancer cells. 40 We have found that SR11238 had very little effect on either the differentiation or clonal proliferation of either the HL-60 and KG-1 (data not shown) leukemic cells or fresh AML cells. Therefore, this class of transcriptional antagonists probably is not a candidate for further clinical consideration as an antileukemic agent.
Several lines of indirect evidence point to the critical role of RAR in the modulation of myeloid proliferation and differentiation. (1) As shown in this study, RXR-selective retinoids have little effect on hematopoietic cells, but those with RAR selectivity are very active. (2) An analog that functioned as a selective RARa antagonist counteracted the ability of ATRA to induce differentiation of HL-60 cells:' (3) Two independent HL-60 sublines that cannot undergo differentiation in the presence of ATRA have mutations in the ligand-binding region of and replacement of the RARa partially restored responsiveness of the cells to Our results suggest that certain combinations of retinoids may have greater therapeutic activity than either alone. Several of these compounds are undergoing independent clinical testing; however, eventual trials using combinations of these retinoids are possible.
